Obinutuzumab with or without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients with Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
Inclusion Criteria
- Patients must have follicular lymphoma (grade I, II or IIIa) confirmed at initial diagnosis and at relapse with identifiable fludeoxyglucose F-18 (FDG) avid disease on PET/CT; patients that have involvement with large cell lymphoma are not eligible
- Patients must not have clinical evidence of central nervous system involvement by lymphoma since the proposed treatment strategies are not designed to address central nervous system (CNS) involvement adequately; if performed, any laboratory or radiographic tests performed to assess CNS involvement must be negative
- Patients must have a whole body or limited whole body PET/CT scan performed within 42 days prior to registration
- Patients must have bone marrow biopsy performed within 42 days prior to registration
- All disease must be assessed and documented on the S1608 FDG-PET/CT assessment form
- The intent is to enroll patients with FL relapsed within 2 years of completing their first course of chemotherapy (CHOP or bendamustine based therapy) + anti-CD20 therapy. Patient is still eligible if he/she received radiation therapy or anti-CD20 therapy prior to chemoimmunotherapy or if maintenance anti-CD20 therapy was administered after chemoimmunotherapy * Patients must have either failed to achieve a complete remission, or must have relapsed within 2 years after completing CHOP or bendamustine-containing chemoimmunotherapy (including an anti-CD20 monoclonal antibody), as measured from the last dose of CHOP or bendamustine; relapsed patients must not have received any intervening chemotherapy * Patients must have received only 1 course of chemotherapy, containing at least 3 cycles of CHOP or bendamustine; (note that no minimum dose of bendamustine is required) * Patients who received any anti-CD20 antibody therapy prior to CHOP or bendamustine are eligible * Patients who additionally received any maintenance anti-CD-20 antibody therapy or consolidative radioimmunotherapy within 2 years of the last dose of the CHOP or bendamustine therapy are eligible * Involved field or involved site radiation is not considered a line of therapy; examples of eligible prior treatment regimens (note this list is not all inclusive): ** 1st line rituximab treatment followed years later by bendamustine rituximab x 4 cycles ** Bendamustine rituximab x 4 cycles ** 1st line rituximab treatment, 2nd line ibritumomab tiuxetan, followed by bendamustine bortezomib rituximab x 6 cycles followed by rituximab maintenance ** Bendamustine obinutuzumab x 3 cycles ** CHOP rituximab x 6 cycles followed by rituximab maintenance
- For all forms of systemic therapy, patients must have completed therapy at least 21 days prior to registration; patients must have completed any radioimmunotherapy at least 84 days prior to registration; patients must have recovered from all treatment related toxicities from these therapies prior to registration
- Patients must not have any prior treatment with any PI3K inhibitor, or lenalidomide
- Patients must have tissue specimens collected prior to registration; patients must be offered participation in biobanking of residual specimens; with patient consent, residuals from the mandatory submission will be banked for future research
- All patients must have a Zubrod performance status of 0, 1 or 2
- Absolute neutrophil count (ANC) >= 1,500/mcL within 28 days prior to registration
- Platelets >= 75,000/mcL within 28 days prior to registration
- Patients must have adequate renal function as documented by a calculated creatinine clearance >= 60 mL/min, within 28 days prior to registration
- Total bilirubin =< 1.5 x institutional upper limit of normal (IULN) (=< 5 x IULN if secondary to lymphoma, Gilbert’s syndrome, or medication related [e.g., indinavir, tenofovir, atazanavir]) within 28 days prior to registration
- Direct bilirubin =< 1.5 x IULN (=< 5 x IULN if secondary to lymphoma) within 28 days prior to registration
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x IULN (=< 5 x IULN secondary to lymphoma) within 28 days prior to registration
- Patients must have an echocardiogram (ECHO) or multigated acquisition (MUGA) scan within 42 days prior to registration with a cardiac ejection fraction >= 45%
- Patients with hepatitis B virus infection must have undetectable hepatitis B virus (HBV) on suppressive therapy and no evidence of HBV-related hepatic damage; patients with hepatitis C virus infection are eligible if complete eradication therapy has been successfully completed, and there is no detectable hepatitis C virus (HVC) or related hepatic damage; patients with known human immunodeficiency virus (HIV) infection are eligible if they meet all of the following criteria in addition to the other protocol eligibility criteria: * Patient must have no history of acquired immune deficiency syndrome (AIDS)-related complications, other than a history of low CD4+ T-cell count (< 200/mm^3) prior to initiation of combination antiretroviral therapy; on study CD4+ T-cell count may not be informative due to leukemia and should not be used as an exclusion criterion if low * Patient must be healthy on the basis of HIV disease with high likelihood of near normal life span were it not for the leukemia * Patient must have serum HIV viral load of < 200 copies/mm^3 * Patient must be on combination antiretroviral therapy with minimal pharmacokinetic interactions with study therapy and minimal overlapping clinical toxicity with protocol therapy; (recommend a regimen of the integrase inhibitor dolutegravir combined with either disoproxil fumarate/emtricitabine or dolutegravir combined with tenofovir alafenamide/emtricitabine) * Protease inhibitors and once daily formulations containing cobicistat are NOT allowed due to potential pharmacokinetic interactions with leukemia therapy * Stavudine and zidovudine (AZT) are NOT allowed because of overlapping toxicity with protocol therapy
- Patients must be able and willing to receive prophylaxis with daily aspirin, low molecular weight heparin, factor X inhibitors or warfarin if randomized to lenalidomide; patients must also be willing to receive pneumocystis jirovecii prophylaxis with sulfamethoxazole/trimethoprim, dapsone, atovaquone or inhaled pentamidine, in the event that they are randomized to TGR-1202; patients unable or unwilling to take any listed prophylaxis are NOT eligible
- Patients must be able to discontinue CYP2C9 substrates with a narrow therapeutic index (e.g. warfarin, phenytoin), if randomized to TGR-1202; patients must discontinue such agents at least 1 week or 5 half-lives prior to beginning protocol therapy (whichever is longer)
- No second prior malignancy is allowed except for adequately treated basal (or squamous cell) skin cancer, in situ cervical cancer or other cancer for which the patient has been disease free for three years
- Patients must have a complete history and physical examination within 28 days prior to registration
- Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy test with a sensitivity of at least 25 mIU/mL within 10-14 days and again within 24 hours prior to starting cycle 1 of lenalidomide; further, they must either commit to complete abstinence (true abstinence is acceptable when this is in line with the preferred and usual lifestyle of the subject; periodic abstinence [e.g., calendar, ovulation, symptothermal or post ovulation methods] and withdrawal are not acceptable methods of contraception) from heterosexual intercourse or begin TWO acceptable methods of birth control: one highly effective method and one additional effective method AT THE SAME TIME, at least 28 days before starting lenalidomide; while taking lenalidomide, during dose interruptions, and for at least 28 days after the last dose of lenalidomide; FCBP must also agree to ongoing pregnancy testing; men must agree to use a latex condom during sexual contact with a FCBP, even if they have had a successful vasectomy; a FCBP is a female who: 1) has achieve menarche at some point; 2) has not undergone a hysterectomy or bilateral oophorectomy; or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months); all patients must be counseled by a trained counselor every 28 days about pregnancy precautions and risks of fetal exposure; NOTE: patients not randomized to receive lenalidomide will not be required to undergo serial pregnancy testing or lenalidomide counseling after registration
- Patients must have lactate dehydrogenase (LDH) and beta-2-microglobulin collected within 28 days prior to registration
- Patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines
- As a part of the Oncology Patient Enrollment Network (OPEN) registration process the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system
Alaska
Anchorage
Arizona
Tucson
California
Anaheim
Antioch
Arroyo Grande
Auburn
Baldwin Park
Bellflower
Berkeley
Burbank
Duarte
Dublin
Fontana
Fremont
Fresno
Harbor City
Irvine
Loma Linda
Los Angeles
Modesto
Mountain View
Oakland
Palo Alto
Panorama City
Rancho Mirage
Richmond
Roseville
Sacramento
San Diego
San Francisco
San Jose
San Leandro
San Marcos
San Rafael
Santa Clara
Santa Cruz
Santa Rosa
South San Francisco
Stockton
Sunnyvale
Vacaville
Vallejo
Walnut Creek
Woodland Hills
Colorado
Aurora
Boulder
Colorado Springs
Denver
Durango
Englewood
Golden
Grand Junction
Greeley
Greenwood Village
Lakewood
Littleton
Lone Tree
Longmont
Loveland
Parker
Pueblo
Thornton
Wheat Ridge
Connecticut
Hartford
New Haven
North Haven
Florida
Gainesville
Jacksonville
Georgia
Atlanta
Savannah
Hawaii
Honolulu
Idaho
Boise
Fruitland
Meridian
Nampa
Post Falls
Twin Falls
Illinois
Bloomington
Canton
Carthage
Chicago
Danville
Decatur
Effingham
Eureka
Galesburg
Geneva
Kewanee
Lake Forest
Macomb
Mattoon
Maywood
O'Fallon
Ottawa
Pekin
Peoria
Peru
Princeton
Rockford
Springfield
Urbana
Warrenville
Indiana
Fort Wayne
Richmond
Iowa
Clive
Des Moines
Fort Dodge
Iowa City
Sioux City
West Des Moines
Kansas
Chanute
Dodge City
El Dorado
Great Bend
Independence
Kingman
Lawrence
Liberal
Manhattan
McPherson
Newton
Parsons
Pratt
Salina
Wellington
Wichita
Winfield
Kentucky
Bardstown
Louisville
Louisiana
Baton Rouge
New Orleans
Massachusetts
Burlington
Michigan
Ann Arbor
Battle Creek
Brighton
Brownstown
Canton
Chelsea
Clinton Township
Dearborn
Detroit
East China
Flint
Grand Rapids
Grosse Pointe Woods
Jackson
Kalamazoo
Lansing
Livonia
Macomb Township
Muskegon
Novi
Pontiac
Port Huron
Reed City
Rochester Hills
Saginaw
Saint Joseph
Sterling Heights
Traverse City
Warren
West Bloomfield
Ypsilanti
Minnesota
Bemidji
Burnsville
Coon Rapids
Deer River
Duluth
Edina
Fergus Falls
Fridley
Hibbing
Maplewood
Minneapolis
Robbinsdale
Rochester
Saint Cloud
Saint Louis Park
Saint Paul
Sandstone
Shakopee
Stillwater
Virginia
Waconia
Willmar
Woodbury
Missouri
Bolivar
Bonne Terre
Cape Girardeau
Jefferson City
Kansas City
Rolla
Saint Louis
Sainte Genevieve
Springfield
Sullivan
Sunset Hills
Montana
Billings
Bozeman
Butte
Great Falls
Kalispell
Missoula
Nebraska
Bellevue
Grand Island
Kearney
Omaha
Nevada
Carson City
Henderson
Las Vegas
Reno
New Hampshire
Lebanon
New Mexico
Albuquerque
New York
Buffalo
Lake Success
Manhasset
New Hyde Park
New York
Rochester
North Carolina
Charlotte
Clinton
Goldsboro
Hendersonville
Jacksonville
North Dakota
Bismarck
Fargo
Ohio
Cincinnati
Cleveland
Columbus
Dayton
Findlay
Marietta
Maumee
Newark
Springfield
Toledo
Westerville
Oklahoma
Oklahoma City
Oregon
Clackamas
Coos Bay
Newberg
Portland
Pennsylvania
Allentown
Bryn Mawr
Collegeville
Danville
Exton
Hazleton
Lewisburg
Media
Paoli
Pottsville
Selinsgrove
West Reading
Wilkes-Barre
Wynnewood
South Carolina
Charleston
Greenville
Greenwood
Spartanburg
South Dakota
Sioux Falls
Texas
Houston
Utah
Salt Lake City
Washington
Edmonds
Longview
Puyallup
Seattle
Vancouver
West Virginia
Charleston
Wisconsin
Ashland
Chippewa Falls
La Crosse
Ladysmith
Madison
Marshfield
Milwaukee
Minocqua
New Richmond
Rice Lake
Wausau
Weston
Wisconsin Rapids
PRIMARY OBJECTIVE:
I. To compare the complete response rate up to 6 cycles after randomization as defined by centrally read positron emission tomography (PET)/computed tomography (CT) (integral biomarker) of 2 targeted therapeutic regimens (obinutuzumab + umbralisib [TGR-1202] or obinutuzumab + lenalidomide) with obinutuzumab + chemotherapy (cyclophosphamide, doxorubicin hydrochloride [doxorubicin], vincristine sulfate [vincristine], and prednisone [CHOP] or bendamustine hydrochloride [bendamustine]) in patients with early relapsing or refractory follicular lymphoma.
SECONDARY OBJECTIVES:
I. To validate the prognostic association of the m7-FLIPI model, demonstrating that the population of follicular lymphoma patients who respond poorly to chemoimmunotherapy are enriched for having a high-risk m7-FLIPI score, and that the score is associated with progression-free survival (integrated biomarker). (Primary translational medicine)
II. To estimate the 30-month sustained complete response rate (CR30) defined by centrally read PET/CT with each of the regimens in this early relapsing or refractory follicular lymphoma population.
III. To estimate best response up to 12 cycles of therapy, progression free survival, duration of response and overall survival with each of the combinations in early relapsing or refractory follicular lymphoma.
IV. To evaluate the adverse effects of each of the regimens in early relapsing or refractory follicular lymphoma.
V. To evaluate the predictive performance of non-invasive genotyping (m7-FLIPI in circulating tumor deoxyribonucleic acid [DNA]) of plasma at study entry relative to standard tumor genotyping (m7-FLIPI) of formalin-fixed paraffin-embedded tumor tissue.
VI. To evaluate the association between the detection of active lymphoma by PET-CT and the detection of circulating tumor DNA in plasma at baseline, after 6 and 12 cycles, and at 30 months after initiation of study therapy.
OUTLINE: Patients are randomized to 1 of 3 arms.
ARM I: Patients receive obinutuzumab intravenously (IV) on day 1 and umbralisib orally (PO) daily on days 1-28. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
ARM II: Patients receive obinutuzumab IV on day 1 and lenalidomide PO on days 1-21. Treatment repeats every 28 days for up 12 cycles in the absence of disease progression or unacceptable toxicity.
ARM III:
PRIOR BENDAMUSTINE-BASED CHEMOTHERAPY: Patients receive obinutuzumab IV on day 1, cyclophosphamide IV on day 1, doxorubicin IV on day 1, vincristine IV on day 1, and prednisone PO on days 1-5. Treatment with obinutuzumab repeats every 21 or 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Treatment with combination chemotherapy repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity.
PRIOR CHOP CHEMOTHERAPY: Patients receive obinutuzumab IV on day 1, and bendamustine IV over 60 minutes on days 1 and 2. Treatment repeats every 28 days for up to 6 or 12 cycles (bendamustine and obinutuzumab, respectively) in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 3 months for 2 years and then every 6 months for 3 years.
Trial Phase Phase II
Trial Type Treatment
Lead Organization
SWOG
Principal Investigator
Paul Michael Barr
- Primary ID S1608
- Secondary IDs NCI-2017-00009
- Clinicaltrials.gov ID NCT03269669